1021/1507US=84-A / Biol/Mol
Reiss M. Development of inhibitors of transforming growth factor-B signaling for therapy: targetin transforming growth factor-B in metastasis: in vitro and in vivo mechanisms. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 609-34. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FATOR TRANSFORMADOR DE CRESCIMENTO - B; ANGIOGENESE; CANCER; MOTILIDADE; RESPOSTA IMUNE; INVASAO; METASTASE; TGF-B DO TIPO I; INIBIDOR DA QUINASE DO RECEPTOR; CRESCIMENTO TUMORAL

1022/1507US=84-A / Biol/Mol
Schlingensiepen KH, Jachimczak P, Fischer-Blass B, Fischer D, Specht H, schmaus S, Schlingensiepen R. Development of inhibitors of transforming growth factor-B signaling for therapy: targeted downregulation of TGF-B2 with AP 12009 in tumor therapy. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 635-51. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

OLIGODEOXINUCLEOTIDOS ANTISENSE; CANCER; GLIOMA MALIGNO; TGF-B; USO TERAPEUTICO

1023/1507US=84-A / Biol/Mol
Naumann U, Weller M. Development of inhibitors of transforming growth factor-B signaling for therapy: modulating TGF-B receptor signaling: a novel approach of cancer therapy. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 653-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; TGF-B RECEPTORES; MOLECULAS PEQUENAS; DOMINANTE NEGATIVO; RECEPTOR SOLUVEL

1024/1507US=84-A / Biol/Mol
De Crescenzo G, Chao H, Zwaagstra J, Durocher Y, O'Connor-McCourt MD. Development of inhibitors of transforming growth factor-B signaling for therapy: engineering TGB-B traps: artificially dimerized receptor ectodomains as high-affinity blockers of TGF-B action. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 671-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FACTOR DE CRESCIMENTO TRANSFORMANTE-B; ANTAGONISTA; BETAGLICAM; ARMADILHA LIGANTE; RECEPTOR ECTODOMINIO

1025/1507US=84-A / Biol/Mol
Ling LE, Singh J, Chuaqui CE, Boriack-Sjodin PA, Corbley MJ, Lepage DJ, Silverio EL, Sun L, Papadatos JL, Shan F, Pontz T, Kam Cheung H, Zhang X, Arduini RM, Mead JN, Newman MN, Bowes S, Josiah S, Lee WC. Development of inhibitors of transforming growth factor-B signaling for therapy: the use of virtual screening in ALK5 kinase inhibitor discovery and validation of orally active ALK5 kinase inhibitors in oncology. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 685-96. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

VIRTUAL; FARMACOFORO; INIBIDOR DE CINASE; ALK5; TGF-B RECEPTOR TIPO I; CRISTALOGRAFIA DE RAIOS X; TGF-B

1026/1507US=84-A / Biol/Mol
Suzuki E, Albelda SM. Development of inhibitors of transforming growth factor-B signaling for therapy: soluble type II transforming growth factor-B receptor inhibits tumorigenesis by augmenting host ntitumor immunity. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 697-706. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; IMUNIDADE ANTITUMORAL; MESOTELIOMA MALIGNO; SOLUVEL DO TIPO II DO RECEPTOR DE TGF-B

1027/1507US=84-A / Biol/Mol
Lacher MD, Korn WM, Akhurst RJ. Development of inhibitors of transforming growth factor-B signaling for therapy: reversal of EMT by small-molecule inibitors of TGF-B type I and II receptors: implications for carcinoma treatment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B RECEPTORES; PEQUENAS MOLECULAS INIBIDORES; EPITELIAL PARA MESEACHYMAL TRANSICAO; EMT; METASTASE; VIRUS COXSACKIE E RECEPTOR ADENOVIRUS; TERAPIA DO CANCRO ADENOVIRAL

1028/1507US=84-A / Biol/Mol
Bandyópadhyay A, Sun L. Development of inhibitors of transforming growth factor-B signaling for therapy: soluble TGF-B type III receptor suppresses malignant progression of human cancer cells. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 723-35. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

ANGIOGENESE; METALOPROTEINASE DE MATRIZ-9; METASTASE PULMONAR; METASTASE OSSEA; BETAGLICAM SOLUVEL; TGF-B; TGF-B TIPO DE INIBIDORES DO RECEPTOR III; TUMORIGENESE

1029/1507US=84-A / Biol/Mol
Hoffmann FM, Cui Q, Lim SK, Zhao BM. Development of inhibitors of transforming growth factor-B signaling for therapy: targeting smad-dependent TGF-B signaling with peptide aptamers. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 737-56. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

APTAMEROS PEPTIDEO; MOTIVO DE PROTEINA; PROTEINA ANDAIME; SMAD; TGF-B INIBIDORES

1030/1507US=84-A / Biol/Mol
Hsu FJ, Teicher BA, McPherson JM. Development of inhibitors of transforming growth factor-B signaling for therapy: rationale for anti-TGF-B antibody therapy in oncology. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 757-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FACTOR DE CRESCIMENTO TRANSFORMANTE-B; IMUNOSSUPRESSAO; METASTASE OSSEA; CARCINOMA DE CELULAS RENAIS; MELANOMA; CANCER DE MAMA; HORMONAL DO CANCER DA PROSTATA REFRATARIOS; CANCER DE PANCREAS; MIELOMA MULTIPLO; LINFOMA DE NAO-HOGGKIN; BIOMARCADORES

1031/1507US=86 / Biol/Mol
Zakeri Z, Lockshin RA. Cell dealth: history and future. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 1-11. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

MORTE CELULAR; APOPTOSE; AUTOFAGIA; MORTE CELULAR AUTOFAGICA; HISTORICO; LISOSSOMA

1032/1507US=86 / Biol/Mol
Salvesen GS, Riedl SJ. Caspase mechanisms. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 13-23. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

CASPASE; MECANISMOS DE CASPASE; APOPTOSSOMO; DISC; IAP; INIBICAO; PROTEASE; ZIMOGENIO; APOPTOSE

1033/1507US=86 / Biol/Mol
Chalah A, Khosravi-Far R. The mitochondrial death pathway. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 25-45. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

VIA DE MORTE MITOCONDRIAL; APOPTOSE; RECEPTORES DE MORTE; MITOCONDRIAS; MEMBRANAS; FOSFOLIPASES; CARDIOLIPINA; LIBERACAO DE FATORES PRO-APOPTOTICOS; CITOCROMO C; FATOR DE INDUCAO DE APOPTOSE; SMAC / DIABLO; HTRA2/OMI; ENDONUCLEASE G; PROTEINAS MITOCONDRIAIS; ATIVACAO DA CASPASE; FAMILIA BCL-2; STRESS OXIDATIVO; CANCER

1034/1507US=86 / Biol/Mol
Melet A, Song K, Bucur O, Jagani Z, Grassian AR, Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 47-79. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

VIAS APOPTOTICAS; PROGRESSAO TUMORAL; TERAPIA DE CANCER; APOPTOSE; INIBIDORES; TRANSDUCAO DE SINAL; ONCOGENE; MAQUINARIA APOPTOTICA; DROGAS QUIMIOTERAPICAS; RESISTENCIA A DROGA

1035/1507US=86 / Biol/Mol
Tan TT, White E. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 81-104. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

SEGMENTACAO TERAPEUTICO; VIAS DE MORTE EM CANCER; MECANISMOS; MORTE CELULAR; CELULAS CANCERIGENAS; APOPTOSE; QUIMIOTERAPIA; TERAPIA ALVO; FAMILIA BCL-2; RECEPTORES DE MORTE; INIBIDORES DO SINAL DE TRANSDUCAO

1036/1507US=86 / Biol/Mol
Hersey P, Zhang XD, Mhaidat N. Overcoming resistance to apoptosis in cancer therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 105-26. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

TERAPIA DO CANCER; RESISTENCIA A APOPTOSE; ONCOGENE; MELANOMA; FAMILIA BCL-2

1037/1507US=86 / Biol/Mol
Humphreys RC, Halpern W. Trail receptors: targets for cancer therapy. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 127-58. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

TERAPIA DO CANCER; RECEPTORES TRAIL; APOPTOSE; ANTICORPOS MONOCLONAIS

1038/1507US=86 / Biol/Mol
Moore VDG, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 159-75. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

MORTE CELULAR; APOPTOSE; FAMILIA BCL-2; BH3; TERAPEUTICA; PEPTIDEOS

1039/1507US=86 / Biol/Mol
Bialik S, Kimchi A. Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 177-200. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

AUTOFAGIA; SUPRESSAO DO TUMOR; AUTOFAGICOS; VIAS DE MORTE CELULAR; DESENVOLVIMENTO DE TUMORES; MORTE CELULAR PROGRAMADA; DAPK; BECLIN 1; MTOR

1040/1507US=86 / Biol/Mol
Kuribayashi K, El-Deiry W. Regulation of programmed cell death by the P53 pathway. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 201-21. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

REGULACAO DA MORTE CELULAR PROGRAMADA; VIA P53; APOPTOSE; TRANSCRICAO; RECEPTORES TRAIL; MORTE CELULAR DEPENDENTES DE P53

Primeira | Anterior | Próxima | Última